Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Hakop Gevorkyan

Internal Medicine Burbank, CA Medical Doctor

NPI 1073689386 CMS profile 185229

333 E Magnolia Blvd Ste 103, Burbank, CA 91502

Open in the dashboard

General payments

$636

20 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$4,752,744 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Hakop Gevorkyan of Burbank, CA is reported in the CMS Open Payments database as having received $636 across 20 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $4,752,744 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 63rd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $356 5
2024 General $24 1
2023 General $31 2
2022 General $75 4
2021 General $49 2
2020 General $23 1
2019 General $77 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Hakop Gevorkyan
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Hakop Gevorkyan were reported at $356. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Hakop Gevorkyan Internal Medicine median Middle half National median
2019 $77 $159 $48–$570 $163
2020 $23 $119 $33–$402 $114
2021 $49 $135 $37–$521 $132
2022 $75 $141 $42–$496 $149
2023 $31 $149 $45–$519 $160
2024 $24 $154 $47–$537 $164
2025 $356 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Amgen Inc. $316 4 payments
  2. AbbVie, Inc. $108 6 payments
  3. Astellas Pharma US Inc $55 3 payments
  4. Novo Nordisk Inc $50 2 payments
  5. Philips Electronics North America Corporation $24 1 payment
  6. Takeda Pharmaceuticals U.S.A., Inc. $23 1 payment
  7. Lilly USA, LLC $23 1 payment
  8. Arbor Pharmaceuticals, Inc. $22 1 payment
  9. Salix Pharmaceuticals, a division of Bausch Health US, LLC $16 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $636 20 payments
Products named General payments · program years 2019–2025
  1. EVENITY $316 4 payments
  2. MYRBETRIQ $55 3 payments
  3. CREON $52 3 payments
  4. UBRELVY $41 2 payments
  5. Ozempic $34 1 payment
  6. XIFAXAN $31 2 payments
  7. LINZESS $30 2 payments
  8. (8874) inCourage $24 1 payment
  9. TRINTELLIX $23 1 payment
  10. Prolia $23 2 payments
  11. Other $98 5 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 266 drugs

Part D claims

27,166

Median for Internal Medicine: 777

Drug cost

$2,656,050

Median for Internal Medicine: $73,373

Branded share of claims

23.4%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Omeprazole-Sodium Bicarbonate Omeprazole/Sodium Bicarbonate Brand 160 $265,901
Janumet Sitagliptin Phos/Metformin Hcl Brand 305 $165,835
Eliquis Apixaban Brand 342 $151,437
Januvia Sitagliptin Phosphate Brand 269 $147,172
Ozempic Semaglutide Brand 148 $146,839
Diclofenac Sodium Generic 373 $137,768
Jardiance Empagliflozin Brand 225 $124,291
Diclofenac Potassium Generic 47 $123,364
Linzess Linaclotide Brand 157 $89,580
Prolia Denosumab Brand 47 $81,089

The 10 drugs with the highest cost, of 266 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 42 billing codes

Paid by Medicare

$165,202

Of which drugs: $4,016

Medicare patients

464

Average age 78

Services billed

2,589

287 women, 177 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 56%
Depression 56%
Diabetes 53%
Alzheimer's or dementia 40%
Osteoporosis 34%
Heart failure 33%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 13 13 $3,709
Vaccine for influenza for injection into muscle 90653 Office 31 32 $236
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 23 29 $28
Influenza vaccine, trivalent derived from cell cultures 90661 Office 12 13 $0

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

20 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record